What is known and objectives The occurrence of dysgraphia after sertraline intake has never been reported. The objective was to describe a case of this adverse drug reaction and present a review of similar cases held in international databases with a discussion of the possible pharmacological mechanisms. Case summary We observed a 60-year-old man who experienced resting tremors, dyskinesia and dysgraphia 2 months after a stepwise increase in sertraline dosing from 50 to 200 mg/day. What is new and conclusion Dysgraphia is a possible adverse drug reaction to sertraline, and we suggest that inhibition of extrapyramidal dopaminergic activity might be the pharmacological mechanism. Dysgraphia, is a pathological state classified within the extrapyramidal isorders, due to the brain dysfunction induced by dementia, Parkinson's disease, delirium or medications acting on neurons. To date no similar report exists in the literature; this is the first report on an association between dysgraphia and sertraline administration. The damage or reduced neurotransmission to the extrapyramidal system induced by sertraline may explain dysgraphia.

A case of dysgraphia induced by sertraline and a review of official spontaneous adverse reaction databases / M. Gentili, P.M. Marinaccio, C. Galimberti, C. Carnovale, S. Antoniazzi, M. Pozzi, E. Clementi, C. Viganò, S. Radice. - In: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. - ISSN 0269-4727. - 41:1(2016), pp. 106-107. [10.1111/jcpt.12356]

A case of dysgraphia induced by sertraline and a review of official spontaneous adverse reaction databases

M. Gentili
Primo
;
C. Galimberti;C. Carnovale;S. Antoniazzi;M. Pozzi;E. Clementi
;
C. Viganò
Penultimo
;
S. Radice
Ultimo
2016

Abstract

What is known and objectives The occurrence of dysgraphia after sertraline intake has never been reported. The objective was to describe a case of this adverse drug reaction and present a review of similar cases held in international databases with a discussion of the possible pharmacological mechanisms. Case summary We observed a 60-year-old man who experienced resting tremors, dyskinesia and dysgraphia 2 months after a stepwise increase in sertraline dosing from 50 to 200 mg/day. What is new and conclusion Dysgraphia is a possible adverse drug reaction to sertraline, and we suggest that inhibition of extrapyramidal dopaminergic activity might be the pharmacological mechanism. Dysgraphia, is a pathological state classified within the extrapyramidal isorders, due to the brain dysfunction induced by dementia, Parkinson's disease, delirium or medications acting on neurons. To date no similar report exists in the literature; this is the first report on an association between dysgraphia and sertraline administration. The damage or reduced neurotransmission to the extrapyramidal system induced by sertraline may explain dysgraphia.
No
English
adverse drug reaction; dysgraphia; pharmacovigilance; sertraline
Settore BIO/14 - Farmacologia
Articolo
Esperti anonimi
Pubblicazione scientifica
2016
Blackwell Publishing Ltd
41
1
106
107
2
Pubblicato
Periodico con rilevanza internazionale
scopus
pubmed
crossref
Aderisco
info:eu-repo/semantics/article
A case of dysgraphia induced by sertraline and a review of official spontaneous adverse reaction databases / M. Gentili, P.M. Marinaccio, C. Galimberti, C. Carnovale, S. Antoniazzi, M. Pozzi, E. Clementi, C. Viganò, S. Radice. - In: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. - ISSN 0269-4727. - 41:1(2016), pp. 106-107. [10.1111/jcpt.12356]
reserved
Prodotti della ricerca::01 - Articolo su periodico
9
262
Article (author)
no
M. Gentili, P.M. Marinaccio, C. Galimberti, C. Carnovale, S. Antoniazzi, M. Pozzi, E. Clementi, C. Viganò, S. Radice
File in questo prodotto:
File Dimensione Formato  
JCPT-3300SertralineDysgraphiaEdit.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 521.75 kB
Formato Adobe PDF
521.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Gentili_et_al-2016-Journal_of_Clinical_Pharmacy_and_Therapeutics.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 475.36 kB
Formato Adobe PDF
475.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/384625
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact